Blueprint Medicines Corporation
http://www.blueprintmedicines.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Blueprint Medicines Corporation
Finance Watch: Public Market Doldrums Have Not Sunk Private Company Funding Yet
ARCH closed a $3bn VC fund to end the month of June while in the same week six public biopharma firms said they are cutting jobs. Even so, some publicly traded companies have been able to launch sizeable offerings, including a $450m note sale by Cytokinetics and Xenon’s $250m follow-on.
Blueprint And Ardelyx Join List Of Biotechs Selling Royalties To Raise Funds
The US firms have added to a growing number of struggling biotech companies that are selling off future royalties to help push promising drug candidates past the finish line.
BMS Hopes Turning Point Buyout Will Fare Better Than Roche’s Ignyta Acquisition
Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.
Triana Launches With $110m Funding For Developing Molecular Glues
The Massachusetts-based biotech’s fundraise will be used to discover and develop molecular glues with an initial focus on cancer targets.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Hoyle Pharmaceuticals, Inc.
- ImmunoCo, Inc.